169 related articles for article (PubMed ID: 10566734)
1. Time course of histological changes in patients with a sustained biochemical and virological response to corticosteroid withdrawal therapy for chronic hepatitis B.
Arase Y; Ikeda K; Murashima N; Chayama K; Tsubota A; Koida I; Suzuki Y; Saitoh S; Kobayashi M; Kobayashi M; Kumada H
Am J Gastroenterol; 1999 Nov; 94(11):3304-9. PubMed ID: 10566734
[TBL] [Abstract][Full Text] [Related]
2. Time course of histological changes in patients with a sustained biochemical and virological response to interferon-alpha therapy for chronic hepatitis C virus infection.
Tsubota A; Kumada H; Chayama K; Arase Y; Saitoh S; Koida I; Suzuki Y; Kobayashi M; Murashima N; Ikeda K
J Hepatol; 1997 Jul; 27(1):49-55. PubMed ID: 9252073
[TBL] [Abstract][Full Text] [Related]
3. Quantification of intrahepatic total hepatitis B virus DNA in chronic hepatitis B patients and its relationship with liver histology.
Bayram A; Erkilic S; Ozkur A; Bayram M; Sari I
J Clin Pathol; 2008 Mar; 61(3):338-42. PubMed ID: 17693576
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B.
van Zonneveld M; Honkoop P; Hansen BE; Niesters HG; Darwish Murad S; de Man RA; Schalm SW; Janssen HL
Hepatology; 2004 Mar; 39(3):804-10. PubMed ID: 14999700
[TBL] [Abstract][Full Text] [Related]
5. Changes in liver histology as a "surrogate" end point of antiviral therapy for chronic HBV can predict progression to liver complications.
Hui CK; Leung N; Shek WH; Zhang HY; Luk JM; Poon RT; Lo CM; Fan ST; Lau GK;
J Clin Gastroenterol; 2008; 42(5):533-8. PubMed ID: 18344885
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of long-term interferon therapy in chronic hepatitis B patients with HBV genotype C.
Sakai T; Shiraki K; Inoue H; Okano H; Deguchi M; Sugimoto K; Ohmori S; Murata K; Nakano T
Int J Mol Med; 2002 Aug; 10(2):201-4. PubMed ID: 12119559
[TBL] [Abstract][Full Text] [Related]
7. Lamivudine monotherapy in HBeAg-negative chronic hepatitis B: prediction of response-breakthrough and long-term clinical outcome.
Manolakopoulos S; Bethanis S; Elefsiniotis J; Karatapanis S; Triantos C; Sourvinos G; Touloumi G; Economou M; Vlachogiannakos J; Spandidos D; Avgerinos A; Tzourmakliotis D
Aliment Pharmacol Ther; 2006 Mar; 23(6):787-95. PubMed ID: 16556181
[TBL] [Abstract][Full Text] [Related]
8. Histological outcome during long-term lamivudine therapy.
Dienstag JL; Goldin RD; Heathcote EJ; Hann HW; Woessner M; Stephenson SL; Gardner S; Gray DF; Schiff ER
Gastroenterology; 2003 Jan; 124(1):105-17. PubMed ID: 12512035
[TBL] [Abstract][Full Text] [Related]
9. [Liver histological changes after lamivudine treating in chronic hepatitis B patients with HBeAg positive].
Jin RH; Lang ZW; Yao GB; Guo XH
Zhonghua Gan Zang Bing Za Zhi; 2003 Sep; 11(9):555-7. PubMed ID: 14552720
[TBL] [Abstract][Full Text] [Related]
10. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease.
Papatheodoridis GV; Dimou E; Laras A; Papadimitropoulos V; Hadziyannis SJ
Hepatology; 2002 Jul; 36(1):219-26. PubMed ID: 12085368
[TBL] [Abstract][Full Text] [Related]
11. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B.
Chang TT; Liaw YF; Wu SS; Schiff E; Han KH; Lai CL; Safadi R; Lee SS; Halota W; Goodman Z; Chi YC; Zhang H; Hindes R; Iloeje U; Beebe S; Kreter B
Hepatology; 2010 Sep; 52(3):886-93. PubMed ID: 20683932
[TBL] [Abstract][Full Text] [Related]
12. Significance of HBV DNA levels in liver histology of HBeAg and Anti-HBe positive patients with chronic hepatitis B.
Yuen MF; Ng IO; Fan ST; Yuan HJ; Wong DK; Yuen JC; Sum SS; Chan AO; Lai CL
Am J Gastroenterol; 2004 Oct; 99(10):2032-7. PubMed ID: 15447768
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B.
Arase Y; Ikeda K; Suzuki F; Suzuki Y; Saitoh S; Kobayashi M; Akuta N; Someya T; Hosaka T; Sezaki H; Kobayashi M; Kumada H
Am J Med; 2006 Jan; 119(1):71.e9-16. PubMed ID: 16431195
[TBL] [Abstract][Full Text] [Related]
14. Clinical and histological outcome after hepatitis B e antigen to antibody seroconversion in children with chronic hepatitis B.
Ruiz-Moreno M; Otero M; Millán A; Castillo I; Cabrerizo M; Jiménez FJ; Oliva H; Ramon y Cajal S; Carreño V
Hepatology; 1999 Feb; 29(2):572-5. PubMed ID: 9918937
[TBL] [Abstract][Full Text] [Related]
15. The predictive value of liver fibrosis in determining the effectiveness of interferon and lamivudine therapies for chronic hepatitis B.
Shindo M; Hamada K; Nishioji K; Muramatsu A; Oda Y; Okuno T
J Gastroenterol; 2004; 39(3):260-7. PubMed ID: 15065004
[TBL] [Abstract][Full Text] [Related]
16. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.
Leung NW; Lai CL; Chang TT; Guan R; Lee CM; Ng KY; Lim SG; Wu PC; Dent JC; Edmundson S; Condreay LD; Chien RN;
Hepatology; 2001 Jun; 33(6):1527-32. PubMed ID: 11391543
[TBL] [Abstract][Full Text] [Related]
17. Long-term therapy of chronic hepatitis B with lamivudine.
Lau DT; Khokhar MF; Doo E; Ghany MG; Herion D; Park Y; Kleiner DE; Schmid P; Condreay LD; Gauthier J; Kuhns MC; Liang TJ; Hoofnagle JH
Hepatology; 2000 Oct; 32(4 Pt 1):828-34. PubMed ID: 11003630
[TBL] [Abstract][Full Text] [Related]
18. The concentration of Fas in the serum and liver tissue in viral chronic hepatitis B patients treated with lamivudine.
Lapinski TW
Hepatogastroenterology; 2005; 52(62):575-9. PubMed ID: 15816481
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcome in children with chronic hepatitis B: a 24-year observation period.
Iorio R; Giannattasio A; Cirillo F; D' Alessandro L; Vegnente A
Clin Infect Dis; 2007 Oct; 45(8):943-9. PubMed ID: 17879906
[TBL] [Abstract][Full Text] [Related]
20. Effect of long-term lamivudine in chronic hepatitis B virus-infected children.
Ozgenç F; Arikan C; Sertoz RY; Nart D; Aydogdu S; Yagci RV
Antivir Ther; 2004 Oct; 9(5):729-32. PubMed ID: 15535410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
